BPTSY OTC

Biophytis S.A. is a clinical-stage biotechnology firm dedicated to developing therapeutic interventions that slow the degenerative processes associated with age and improve functional outcomes for patients. The company's innovative treatments work by targeting and activating vital biological resilience pathways. These mechanisms are designed to protect against and counteract various biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral factors, which are known to contribute to age-related diseases. The company's leading investigational compound is BIO101, an orally administered small molecule. It is currently being developed for neuromuscular conditions such as sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as for managing severe respiratory failure in individuals afflicted with COVID-19. Biophytis is also advancing BIO201, another orally delivered small molecule, intended for the treatment of retinopathies, specifically dry age-related macular degeneration and Stargardt disease. The firm has a collaboration agreement with AFM-Telethon focused on the development of BIO101 for DMD. Established in 2006, Biophytis S.A. is headquartered in Paris, France.